This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, potentially limiting patients’ ability to access it.
At a medical conference, the companies detailed clinical trial results that could help support approval of their drug, lecanemab. However, some doctors aren’t yet convinced the medicine’s risks are worth its potential benefits.
But uptake could be slow as insurers and doctors weigh the drug's safety and cost-effectiveness. Leqvio, which Novartis acquired for nearly $10 billion two years ago, arrives with high sales expectations.
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.
While some see the new donanemab results as adding to a “watershed moment” in Alzheimer’s research, others say they reinforce the limitations of so-called anti-amyloid therapies.
Interim study data suggest the Danish drugmaker can remain in the race to develop new kinds of weight loss drugs as doctors seek alternatives to the now dominant GLP-1s.
QUICK READ: Patients are returning to their doctor’s office, and it’s not uncommon for appointments, or routine visits, to be scheduled weeks or months in advance. When I sent an email to my doctor’s office, I was shocked when she said the earliest appointment she had for physicals was in September.
Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.
Michel Vounatsos, Biogen's CEO since 2017, will be replaced as the company "substantially" eliminates the commercial workforce around Aduhelm, which has generated paltry sales in the face of resistance from insurers and doctors.
The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.
Relyvrio, a drug developed by Amylyx Pharmaceuticals, is in high demand in ALS clinics across the U.S. Though some patients are already getting it, insurance coverage and out-of-pocket costs remain a source of anxiety.
The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.
The availability of three vastly different, cutting-edge medicines for the rare disease has put patients, families and doctors in an unfamiliar position.
Nearly two months since Aduhelm became available, many physicians have yet to use the first treatment approved in the U.S. to slow Alzheimer's disease.
A quarter century after Roche's Herceptin became an option for HER2-positive breast cancer, positive study results for Enhertu could push doctors to consider a new classification of "HER2 low" disease.
Enhertu is the first targeted treatment cleared for breast cancers that are ‘HER2 low,’ a new classification that could change how doctors treat the disease.
Drugs like Ozempic are very effective at helping most people who take them lose weight. Semaglutide (sold as Wegovy and Ozempic) and tirzepatide (sold as Zepbound and Mounjaro) are the most well known in the class of drugs that mimic hormones to reduce feelings of hunger. But does weight come back when you stop using […]
SUMMARY: The media headlines promise weight loss for diabetes patients, but Norvo’s new drug is in the same class as other drugs and carries many warnings. Can diabetes patients really stay adherent to a drug for 63 weeks in which 85% of patients report GI side effects and will insurance cover the cost?
And the Covid-19 pandemic only underscored that obesity puts people at greater risk for infectious disease but are new weight loss drugs the answer? Unpaid celebrity endorsements include venture capitalist Marc Andreessen, who says the drug completely changed his relationship with food, and Elon Musk, who has cited it on Twitter.
Another TED talk on the evils of prescription drug marketing was filled with misinformation as usual. Today consumers don’t run to their doctor after seeing a DTC ad, they do their research, and in some cases, the ads actually help them identify potential health problems. What about marketing to doctors?
Treatment with Wegovy led to a 20% reduction in the relative risk of cardiovascular complications or death, a finding that could further shift how doctors treat obesity.
Aduhelm sales totaled just $1 million in the fourth quarter as Biogen struggles to win over doctors and insurers. The company said it would reduce expenses by more than currently planned if Medicare limits coverage.
Researchers in the US have developed an artificial intelligence-based tool that is able to predict COVID-19 symptoms and suggest which FDA-approved drugs might be used to treat patients. The post AI tool may help doctors select best drugs for COVID patients appeared first on.
The passage of the Inflation Control bill is an excellent first step in limiting high drug costs, but our healthcare system is still built for profit at the expense of patients. First, the health insurance companies are making a lot of money while burying doctors in paperwork and limiting treatment options. The result:? The result:?
SUMMARY: DTC marketing is not the reason why prescription drugs cost so much. Today, people don’t see a DTC TV ad and run to their doctor to ask for an Rx. They research the drug online and ask their physician about it if they decide it’s a treatment option. Still, the gatekeeper continues to be their doctor.
Accelerated Approval allows for early access to drugs and biologics based on initial evidence of safety and effectiveness, while confirmatory studies required to verify clinical benefits are ongoing. The program was codified into law under the Food and Drug Safety and Innovation Act (FDASIA) in 2012. Do patients care? Of course not.
Positive results from a late-stage clinical trial of the drug, called lecanemab, were a surprising success for a field used to setbacks. But doctors and researchers point out that the reported benefit appears relatively modest.
SUMMARY: Physicians are tired and overwhelmed with medical information on new drugs. A client launched an Oncology drug based on extensive research with physicians, but the results were not that good during a post-launch evaluation. 4our: There are too many messages associated with new drugs. It’s a huge challenge.
When visiting a doctor, it’s pretty common to see a doctor going from room to room with laptops. More and more, I am hearing that pharma is NOT part of the digital conversation while talking to other doctors and going to independent health resource sites. It’s no secret that HCPs are using digital more and more.
Yet the media has led with “diabetes drug leads to major weight loss” Will doctors inform patients? The drug carries a potential risk for a type of thyroid tumor and has a boxed warning. This drug can be effective if patients follow the directions for weight loss.
The pharmaceutical industry often relies on enzymes to perform a process known as biocatalysis, which facilitates the cost-effective and sustainable production of small molecule drugs at scale. The post Enabling the next wave of innovative drug therapies with speciality enzymes appeared first on Pharmaceutical Technology.
SUMMARY: The FDA is coming under intense pressure to approve Biogen’s Alzheimer’s drug, but Aaron S. ” For Biogen, the stakes are high as approval is likely to earn tens of millions, of to billions, in profits but is hope a reason to approve a drug over science? .” Biogen needs a new drug revenue badly.
Although the drug is legal in Michigan, doctors in the state are hesitant to authorize their patients to use cannabis, while struggling to manage other influences on their patients' health care decisions, says a University of Michigan researcher.
On the other hand, we did make a thought elder, who worked on clinical trials of a cancer drug, to take questions from other physicians about those clinical trials. Finally, after the storm of the pandemic, many doctors re suddenly overwhelmed with patients. When using the Internet to reach doctors, numbers don’t matter.
Doctors have long asserted that prior authorization — the need to get approval from the patient’s insurer before proceeding with treatment — causes delays that can hurt patient care. Prior authorizations also exact a toll on doctors, who say the paperwork has gotten out of hand. Then there is prior authorization.
SUMMARY: Online health seeker numbers are still very high, indicating that people are doing their research first before asking for a prescription drug. Online ads for prescription drugs are unique. Nobody will see an online ad for a prescription drug and ask their doctor about it without doing some research first.
The Center for Drug Safety and Effectiveness at Johns Hopkins University has led a study into prescription drug use of multiple concurrent central nervous system (CNS)-active drugs.
The National Medical Products Administration (NMPA) of China has granted conditional approval for two domestically developed oral drugs to treat Covid-19. Simcere Pharmaceutical Group and Shanghai Junshi Biosciences’ subsidiary have submitted the applications for the two drugs Xiannuoxin (SIM0417) and VV116, respectively.
Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S. Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages.
The patient, who has a severe shellfish allergy, recovered quickly with treatment. Until now, reports of severe reactions had been linked to the Pfizer vaccine.
doctors can now choose Amjevita instead, the first of several close copies of the popular rheumatoid arthritis drug expected this year. But industry-watchers warn consumer savings may be limited. Image credit: JB Reed/Bloomberg via Getty Images)
IN SUMMARY : When patients return to doctor’s offices will HCP’s have time to go online with every drug company that requests an online detail? Back to HCP’s…digitization can’t replace the relationships that pharma reps and MLS people build with doctors. As for patients?
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content